Fundz

Logex Announces Investment From Thoma Bravo

PRIVATEMar 01, 2023

Round Type

Venture

AmsterdamInformation TechnologyHealth CareAnalytics

Investors

Summa EquityThoma Bravo

Description

LOGEX, a European healthcare analytics provider, today announced an investment from Thoma Bravo, a leading software investment firm. LOGEX's existing shareholders, the company's founders, and Summa Equity will remain invested with the business and will work closely with Thoma Bravo and the executive committee to support LOGEX's European growth and further drive innovation in healthcare analytics.

Quick answer

LOGEX raised an undisclosed amount in a funding round, dated March 1, 2023. Investors: Summa Equity and Thoma Bravo. LOGEX is based in Amsterdam, New York, United States.

How much did LOGEX raise?
LOGEX raised an undisclosed amount in a funding round on March 1, 2023.
Who invested in LOGEX?
Summa Equity and Thoma Bravo are named as investors in this round.
What does LOGEX do?
Turning data into better healthcare, that is our mission.
Where is LOGEX based and how big is it?
LOGEX is based in Amsterdam, New York, United States.

Source: Fundz verified event record.

Who else raised in Analytics and Health Care around the same time

Companies in the same sectors as LOGEX that raised within 45 days of this round, from Fundz verified event records.

  • ImageTrend raised an undisclosed amount on February 10, 2023.
  • Stride raised $750K (Seed) on February 3, 2023.
  • Evigence raised $18M (Series B) on January 17, 2023.
  • TransCode Therapeutics raised an undisclosed amount on April 14, 2023.
  • Little Journey raised $3.1M (Seed) on April 14, 2023.
  • Lapix Therapeutics raised $5.9M on April 14, 2023.

Who to call at LOGEX, and when

A new round usually means LOGEX is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day LOGEX raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LOGEX, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LOGEX. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

LOGEX

Location

Amsterdam, New York, United States

About

Turning data into better healthcare, that is our mission. We empower stakeholders at every level of the healthcare system by bringing clarity to decisions that result into the best possible healthcare. LOGEX is headquartered in Amsterdam, with over 350 international experts working in ten countries across Europe. To learn how LOGEX can bring clarity to your healthcare data, visit logex.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment LOGEX raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for LOGEX's next move

See what Strategic adds

LOGEX raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.